Spravato (esketamine) has emerged as a groundbreaking treatment for individuals struggling with treatment-resistant depression (TRD). At Waybridge, we offer Spravato as part of our commitment to providing advanced interventional treatments for depression. In this overview, we explore the history, typical treatment methods, and insurance coverage related to Spravato to help you understand how this innovative therapy might support your journey toward mental wellness.

The History of Spravato

Spravato is a nasal spray formulation of esketamine, a derivative of ketamine—a medication initially developed in the 1960s as an anesthetic. Over time, research indicated ketamine’s potential to rapidly alleviate depressive symptoms in patients who did not respond adequately to traditional antidepressants.

Recognizing this potential, extensive clinical trials were conducted, leading to the FDA approval of Spravato in 2019 specifically for treatment-resistant depression. Since then, Spravato has provided a powerful new option for patients needing fast, effective relief.

How Spravato Works

Spravato functions differently from traditional antidepressants by targeting the brain’s glutamate system, which plays a crucial role in mood regulation and neural connectivity. By acting on this system, Spravato helps rapidly alleviate symptoms of depression.

Patients typically experience relief much faster than with traditional antidepressants, often noticing improvements within days or even hours of treatment.

Common Treatment Approaches

Spravato treatment at Waybridge is carefully administered under medical supervision due to its potent effects. Here’s what a typical treatment course involves:

• Administration: Spravato is administered as a nasal spray in a clinical setting.
  
  
• Treatment Frequency: Initial treatments typically occur twice weekly for the first four weeks, followed by weekly or bi-weekly maintenance sessions.
  
  
• Monitoring: Due to possible short-term side effects like dizziness or dissociation, patients are monitored at the clinic for approximately two hours after administration.
  
  

Side Effects and Safety

Spravato is generally well-tolerated, but some patients may experience mild side effects, including:

• Dizziness or vertigo
  
  
• Nausea
  
  
• Dissociation (a temporary feeling of detachment)
  
  
• Increased blood pressure
  
  

These side effects are typically short-lived and resolve quickly after the treatment session. Because of these potential effects, Spravato treatments are always performed under medical supervision.

Insurance Coverage for Spravato

As an FDA-approved treatment for treatment-resistant depression, Spravato is covered by many major insurance providers, including Medicare and several private insurers. Coverage typically requires:

• Diagnosis of treatment-resistant depression (TRD)
  
  
• Documented inadequate response to previous antidepressant treatments
  
  
• Pre-authorization and referral from a psychiatrist or qualified healthcare provider
  
  

At Waybridge, our knowledgeable administrative staff can help you navigate the insurance process to maximize your coverage and minimize out-of-pocket costs.

Why Choose Spravato Treatment at Waybridge?

At Waybridge, we specialize in innovative therapies like Spravato, IV ketamine, and Transcranial Magnetic Stimulation (TMS) for challenging depressive conditions. Our approach combines compassionate care, personalized treatment plans, and close coordination with your existing healthcare providers to ensure holistic support.

Taking the Next Step

If traditional treatments haven't provided adequate relief from your depression, Spravato therapy could be the solution you've been seeking. Contact Waybridge today to learn more about our Spravato treatment options, insurance guidance, and how we can support your path toward mental health recovery.

‍